Sign In
Buy VXRT
$0.534
-0.0118 (-2.16%)
At Close: Jul 13, 2026
No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
04:00pm, Wednesday, 01'st Jul 2026
Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees
Details Strategic Actions Taken by the Board to Advance the Company's Pipeline and Drive Value Creation Vaxart's Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Gro
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
08:00am, Thursday, 25'th Jun 2026
Latest Modification is Important Required Step to Releasing 12-month Data from 400-participant Sentinel Cohort Funding to Advance Data Analysis from More Than 5,000 Trial Participants Ahead of Key Tri
Urges Stockholders to Vote “FOR” ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Cali
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
08:00am, Monday, 15'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprieta
Vaxart to Participate in BTIG Infectious Disease Day 2026
08:00am, Tuesday, 09'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprieta
Mails Letter to Shareholders Detailing Strength of the Board's Nominees and Momentum in Advancing Vaxart's Value Creation Strategy Reinforces that the Dissident's Nominees Have No Relevant Biotechnolo
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
08:18am, Monday, 01'st Jun 2026
Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
04:01pm, Tuesday, 19'th May 2026
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
08:31pm, Friday, 08'th May 2026
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second qua
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
08:00am, Friday, 01'st May 2026
Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company's s
Vaxart (OTCMKTS:VXRT) Stock Passes Above 50-Day Moving Average – Time to Sell?
04:20am, Friday, 24'th Apr 2026
Shares of Vaxart, Inc. (OTCMKTS:VXRT - Get Free Report) passed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.68 and traded as high as $0.76. V
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
04:30pm, Thursday, 23'rd Apr 2026
Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform
